B+
Bull case
20%
Probability
Target price
$40.00
Analysis reference price unavailable
Analysis 2026-08-04 · RankAlpha Sentiment Codex
SRZN
SurrozenBNasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
Quote time unavailable
Current thesis
The bull case is a timely SZN-8141 IND, subsequent clearance, continued SZN-8143 progress, and further validation from the Boehringer relationship. Cash and the partner milestone provide useful near-term support.
Posture
Constructive
Lead driver
Sentiment
What changed
Sentiment remains the lead driver in the composite, 7D delta +16.5.
What can break
A reported 10% owner open-market sale may contribute to sentiment overhang but is not evidence of operating deterioration. [#SEC-FORM4-2026-07-24]
Momentum
17
Value
41
Sentiment
86
Setup hits (3d)
0 · Net Neutral
AI TargetsBase $24.00 · Bull $40.00 · Bear $12.00Analysis 2026-08-04; returns require an exact persisted reference.
Data freshness
Prices
Unavailable: Price unavailable
Fundamentals
As of 2026-08-17 • Vendor: Data Vendor v1
Scores
As of 2026-09-09 • Model: HYBRID_IC_RP
AI Memo
As of 2026-08-04 • Model: RankAlpha Sentiment Codex
Investment thesisAs of 2026-09-09
Investment thesis
As of 2026-09-09
Grade is the composite factor band; factor scores use a 0–100 scale. Confidence describes evidence quality, not a probability of return. Score date: 2026-09-09. Definitions
Supporting evidence
What
Grade B · Constructive
Confidence Medium · Net Neutral
Target $44.60
Why
Momentum17 · Δ7d -7.3
Value41 · Δ7d 0.0
Sentiment86 · Δ7d +16.5
So what
Strength-led posture (Net Neutral). Favor watchlist adds and disciplined entries.
Confirming evidence
- • Sentiment remains the lead driver in the composite, 7D delta +16.5.
Contradictions & invalidation
- • A reported 10% owner open-market sale may contribute to sentiment overhang but is not evidence of operating deterioration. [#SEC-FORM4-2026-07-24]
- • Failure to submit or clear the SZN-8141 IND on schedule could remove the principal near-term catalyst.
- • The bear case is an IND delay or negative regulatory interaction, continued preclinical-only evidence, rising development expenses, financing dilution, and weak follow-through after the initial update.
Catalyst clock
2026-08-04
Cash and partner-milestone support
Lead driver: Sentiment · See AI snapshot
Momentum
17
9% active weight
Current posture
7d trendSoftening
Δ7d
-7.3
Δ21d
-16.8
Value
41
28% active weight
Current posture
7d trendFlat
Δ7d
0.0
Δ21d
+0.1
Sentiment
86
62% active weight
Current posture
7d trendImproving
Δ7d
+16.5
Δ21d
+22.2
Why this grade
Composite grade B. Momentum 17.2 / Value 41.2 / Sentiment 85.5
Scenario snapshot
Scenario probability is memo-authored likelihood, not forecast certainty. Targets belong to the analysis dated 2026-08-04. Scenario method
Most likely
B
Base case
50%
Probability
Target price
$24.00
Analysis reference price unavailable
Analysis 2026-08-04 · RankAlpha Sentiment Codex
B-
Bear case
30%
Probability
Target price
$12.00
Analysis reference price unavailable
Analysis 2026-08-04 · RankAlpha Sentiment Codex
Fundamentals (TTM)As of 2026-08-17
Fundamentals (TTM)
As of 2026-08-17
Market Cap
$279.5M
Beta
0.58
Shares Out
11.75M
P/E (TTM) · Derived
-0.7
P/S (TTM)
45.43
P/FCF (TTM) · Derived
-7.49
Rev YoY
+408.6%
EPS YoY
-115.9%
Gross Margin
+98.1%
Op Margin
-385.3%
Net Debt
-$82.61M
Current Ratio
12.14
As of 2026-09-09 • Updated nightlySource: Internal modelMethods & Data